


Imaging, quantifying and targeting hallmarks of cancer


Ivan Ho Shon


Disclosures

- Amplificare Pty Ltd




Hanahan D, Weinberg R; The Hallmarks of Cancer. Cell 2000 100(1), 57 - 70










Imaging



FDG PET










<https://www.nobelprize.org/prizes/medicine/1931/summary/>
















^{68}Ga PSMA

A



^{68}Ga dotatate

Why image the hallmarks of cancer?

- Basic science
- Detection
- Prognosis
- Response assessment
- Biomarker of MoA
- Identify theranostic targets

Quantifying

Quantifying Hallmarks of Cancer



- Standardised uptake value (SUV)
 - If the tracer were distributed *uniformly* $SUV = 1$ everywhere
 - Areas with higher than average uptake have $SUV > 1$
 - SUVs potentially allow inter and intra-patient comparisons
 - Confounders
 - For FDG predictive of malignancy, proliferation, tumour grade, prognosis




Quantification in molecular imaging

$$SUV_{max} = \frac{C_{max} \text{ (Bq/cc)}}{A_{inj} \text{ (Bq)} / W \text{ (g)}}$$








$$SUV_{peak} = \frac{C_{1cm^3 \text{ ROI}} \text{ (Bq/cc)}}{A_{inj} \text{ (Bq)} / W \text{ (g)}}$$







$$SUV_{mean} = \frac{C_{ROI} \text{ (Bq/cc)}}{A_{inj} \text{ (Bq)} / W \text{ (g)}}$$









-  SUV_{max}
-  SUV_{peak}
-  SUV_{mean} (MATV)

Metabolic Tumour Volume
Total Lesion Glycolysis









Biological heterogeneity

- Proliferation / metabolism
- Cellular density
- Necrosis
- Fibrosis
- Perfusion /angiogenesis
- Hypoxia
- Receptor expression



Heterogeneity and Radiomics

- Clinical reporting
 - “there is *heterogeneous* intense tracer uptake, SUVmax.... in the *irregular* mass...”
- Quantifying heterogeneity
 - “Radiomics focuses on improvements of image analysis, using an automated high-throughput extraction of large amounts (200+) of quantitative features of medical images..”
 - Lambin P et. al. Eur J Cancer. 2012 Mar;48(4):441-6.
- Artificial Intelligence

Radiomics



- Advantages

- Applicable to all imaging modalities
 - Significance modality dependent
- Use existing data

- Disadvantages

- Biologic relevance
- Harmonisation
 - Binning
 - Mathematical
 - Computational
- Oversampling / overlap

Targeting



RADIO-IODINE HALTS ONE TYPE OF CANCER

Radioactive chemical brings about history-making recovery of patient dying from thyroid tumors

The man shown in the contrasting picture at right is a Brooklyn shoe salesman named Bernard Brunschtein who is destined to become one of the most famous patients in medical history. Brunschtein is the first person known in the world in whose case cancer can be established by medical tests on a living patient of metastatic cancer, a form of the disease in which the malignancy spreads through the body from its original tumor.



BERNARD BRUNSCHTEIN (IN THE LEFT), AS HE LOOKS TODAY

...cancer has always been 100% fatal. But Brunschtein's tumor was destroyed in a simple, almost miraculous way by the breathing of ten doses of radioactive iodine.

When Brunschtein was admitted to New York's Montefiore Hospital seven years ago he appeared to be suffering from an excessive thyroid gland (rather than from cancer). He had a very fast heart and quivering hands, and he was weak and emaciated. But examination revealed that he had no thyroid gland. It had been removed by surgery 19 years before when it had become cancerous. Apparently some of the cancer cells had slipped off, however, and had been carried through the circulatory system to other parts of his body: eight cancerous tumors were found growing from the patient's lungs, ribs, larynx, spine, pelvis and skull. The tumors, comprised of malignant thyroid tissue, were recurring hammer and were otherwise behavior like thyroid glands.

Radioiodine was given to Brunschtein on the theory that his thyroid-like tumors would absorb the drug just as a normal thyroid gland picks up ordinary iodine. If they did, they would be destroyed. For while radio-

iodine is chemically identical with ordinary iodine, it gives off a powerful radiation that can kill any tissue that absorbs it in sufficient concentration. The chemical had never been effectively used as a treatment for cancer, but Brunschtein agreed to try it in the hope that it might help. It did. Three months after he drank his first glassful of the tasteless, colorless liquid, his heart began to slow down and he started to gain weight. Cx-ray counter plates placed over the tumor sites revealed that there was a heavy concentration of radioiodine in these areas. After three additional doses the tumors slowly began to diminish in size and eventually disappeared altogether.

Last May a section of Brunschtein's skull was removed for a microscopic examination of the site of one of the tumors. Only one tumor and dead cells remained, and not a single living cancer cell was found (right).


From his experience with Brunschtein and subsequent cases Dr. S. M. Susslin of Montefiore Hospital, an endocrinologist and a pioneer in radiotherapy, has deduced that radioiodine does not work in many ordinary thyroid cancer cases because most of the chemical is picked up by the thyroid gland itself, and little of it gets to distant tumors. But if the gland is destroyed, the medicine has a better chance of reaching the distant ones. Of a group of 12 patients treated by Susslin since 1941, two appear to be recovering and in two others the tumors have stopped growing. Of the four who died, two had their lives prolonged several years, two were near death when treatment was started, and one died of a different disease.




TUMOR IS LOCATED: in a woman patient's back, with help of an X-ray photo which shows where cancer has penetrated spine (arrow). Exact position of tumor


will be found by using Cx-ray counter to measure the reflection from the fluorescent area (circle 2) in comparison with the surrounding area marked with other circles.

CONTINUED ON NEXT PAGE 55







Anaplastic carcinoma




BRAFV600E




Thyroglobulin




Ki67




Well differentiated papillary carcinoma



BRAFV600E





Thyroglobulin



Ki67


FDG PET CT

I-131 SPECT CT



Anaplastic

Papillary



Research Development Workshop

- Imaging, quantifying and targeting hallmarks of cancer
- Translational or novel molecular imaging / theranostics may form the core of a molecularly targeted clinical trial across tumour streams
- Novel and SoC molecular imaging may be additional endpoints to molecularly targeted clinical trial across tumour streams
- Image banking

Research Development Workshop

- Radiation and Research
 - Australian Radiation Protection and Nuclear Safety Agency
 - Code of Practice for the Exposure of Humans to Ionizing Radiation for Research Purposes
 - “This research study involves exposure to a small amount of radiation. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose from this study is about... mSv. The dose from this study is comparable to that received from many diagnostic medical x-ray and nuclear medicine procedures. At this dose level, no harmful effects of radiation have been demonstrated as any effect is too small to measure.”